Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Efficacy of VDPHL01 in Males and Females With AGA
Sponsor: Veradermics, Inc.
Summary
This study will evaluate the safety and efficacy of VDPHL01 in male and female subjects with Androgenetic Alopecia (AGA). AGA (or pattern of hair loss) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablets for males and VDPHL01 4.5 mg Tablets for females are an investigational oral drug to treat male and female pattern baldness. This multiple center, open-label, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13). Male subjects that meet the study eligibility criteria will be administered VDPHL01 once daily for 12 months. Female subjects that meet the study eligibility criteria will be administered VDPHL01 either once or twice daily for 12 months.
Official title: An Open-Label Multi-Dose Study to Evaluate the Safety and Efficacy of VDPHL01 in Male and Female Subjects With Androgenetic Alopecia
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
70
Start Date
2024-07-08
Completion Date
2026-08
Last Updated
2025-11-06
Healthy Volunteers
No
Interventions
VDPHL01
VDPHL01 Extended Release (ER) Tablet
Locations (4)
01
San Diego, California, United States
04
New Albany, Indiana, United States
03
Hackensack, New Jersey, United States
02
South Jordan, Utah, United States